peter boonen response to my concerns

Thought his response was worth sharing, there is nothing that has not been shared in recent annoucements however may helps us all to get this into perspective. Turing a company around such as Peter has managed to do is no easy feat, therefore time and patience should see the reward. His letter below

Hi,

As we have advised the market, we are rebuilding a company. Our launch in the US of our botanical products, including ImmunoXel, is not a simple affair as we need to address all compliance matters. All our products require re-labelling, re-packaging and bottling to be compliant in the US as well as similarly for other markets. This is no small exercise by any means and involves the engagement of external experts as well as contract bottlers and packagers that are licensed for (in the US case) for production for the US market. As advised we are looking to have product in the US for sale in their upcoming flu season which is about as quickly as we can get it out there.

With regard to ProVale, we are continuing to get agents in place and our major marketing drive starts at our conference in Mexico later this month and we would reasonably expect product sales to start to happen from thereon.

Out TB, TB/HIV product initiative is as one would expect a very much regulatory driven process - so although we have a very effective natural botanical product, it does need to be marketed through governments and the medical profession and to do this we need regulatory approvals which are all in process - as we have also advised the markets.

Believe me, I like yourself and others, would like to see sales explode next week, however it is not that easy regardless of how well we are positioned with product and opportunity.

Further, I fully realise that our share price of recent has been under some selling pressure which would most likely be the result of the Company having had to put together funding commitments when our share price was $0.003 Bid and now many of the early placement and Note conversion shares are being sold. This situation is an unfortunate reality, however we are still at a significant increase over the $$0.003 Bid of some six months ago and I would suggest that as we progress in the near term as well as commercially over the next 12 months, the market should sooner or later come to the realisation that we are a very under valued proposition - as I have also presented in our last Company Presentation.

Thank you for your continued interest and support.

Regords,

Peter Boonen